BioCryst
Pharmaceuticals BCRX announced today that in response
to recent events and an assessment of its assets, the Company is
restructuring and implementing a focused strategy to advance its
hereditary angioedema (HAE) and antiviral programs. The restructuring is
intended to significantly reduce BioCryst's cost structure and scale the
organization appropriately for its current portfolio. The Company plans
to direct its cash and other resources primarily to enable the
achievement of important near-term milestones for the BCX4161
HAE, BCX4430 broad spectrum antiviral and BCX5191
hepatitis C (HCV) programs.
“The strategic focus and restructuring announced today is based on an
evaluation of our programs and operations, following
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in